MILAN, September 22, 2010 /PRNewswire/ -- After having handled the worldwide launch of tapentadol, the innovative drug for the severe acute pain, Alberto Grua has been appointed Grünenthal Europe and Australia Executive Vice President. Beyond the responsibility of the Grünenthal subsidiaries Grünin both continents, Grua will be also a member of the Group Operating Committee of Grünenthal Corporation.

(Photo: http://www.newscom.com/cgi-bin/prnh/20100922/409552 )

Previously, Grua was Responsible for marketing and sales at BayerHealthCare, and then Managing Director of the Italian subsidiary of Grünenthal.

Grua has a business background and graduated in Business Administration at Bocconi University of Milan.

Grünenthal, a multinational company with head office in Aachen, Germany, is leader in pain therapy with drugs of great success. Tapentadol - discovered by Grünenthal and codeveloped with Johnson Johnson Pharmaceutical Research Development, L.L.C, - has been already launched in U.S., while in Europe it is ongoing marketing.

SOURCE: GrSOURCE: ünenthal

CONTACT: Maria DAcquino, +39-02-36557237